Article
May 05, 2016.
The Cell and Gene Therapy Catapult's survey of GMP cell and gene therapy manufacturing facilities in the UK highlights a number of key changes in the cell and gene therapy manufacturing landscape over the last 12 months, including:
Keith Thompson, CEO at the Cell and Gene Therapy Catapult, commented: “The data in the 2016 report shows growth across all the markers that we analyse and forecasts a considerable increase again in the next 12 months."
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.